Expanding CDMO sales to advanced regenerative medical devices with the capability to handle 7 메이저 바카라사이트 굿모닝 types
[by Kang, In Hyo] Pharmicell announced on May 27 that it has completed the expansion of the scope of ‘cells handled by human cell management business,’ with the aim to expand its contract development and manufacturing (CDMO) capabilities for cell therapy.
With the inclusion of additional cell types, 메이저 바카라사이트 굿모닝 is now equipped to manage a total of seven cell types, including bone marrow-derived mononuclear cells, as well as autologous and allogeneic mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, and umbilical cord sources. This development has notably enhanced the company’s capacity for cell manufacturing and supply. 메이저 바카라사이트 굿모닝 emphasized that this advancement lays a foundational framework for full-scale implementation of its CDMO operations, specifically aimed at supporting regenerative medicine institutions.
메이저 바카라사이트 굿모닝 stated that, in addition to cell manufacturing and supply, it also offers contract testing services like sterility testing, mycoplasma contamination testing, and exogenous virus detection. Through the establishment of a comprehensive quality management system, the company has secured differentiated competitiveness as a CDMO partner in the field of cell therapy.
According to 메이저 바카라사이트 굿모닝, the company has over two decades of experience in the production and quality management of stem cell therapies. 메이저 바카라사이트 굿모닝 is equipped with advanced GMP-compliant manufacturing facilities, a robust production infrastructure grounded in human cell management, highly skilled professional personnel, and a well-established system for testing and evaluation.
Leveraging these capabilities, 메이저 바카라사이트 굿모닝 is positioning itself as a specialized CDMO organization that covers the entire development cycle, from early-stage R&D to clinical trials and commercialization. The company stated that it intends to further reinforce its role as a strategic partner in the Korean and international advanced regenerative medicine industry, grounded in its advanced manufacturing system and quality management capabilities.
“We intend to provide comprehensive support to advanced regenerative medicine institutions, encompassing clinical research, cell therapy manufacturing process development, establishment of quality management systems, and therapeutic consulting,” a 메이저 바카라사이트 굿모닝 official stated. “We will actively leverage our specialized mesenchymal stem cell culture medium, ‘PharmiSTEM hMSC Media,’ to spearhead the rapidly growing advanced regenerative medicine market.”